Avelox I.V. en es it fr

Avelox I.V. Brand names, Avelox I.V. Analogs

Avelox I.V. Brand Names Mixture

  • No information avaliable

Avelox I.V. Chemical_Formula


Avelox I.V. RX_link


Avelox I.V. fda sheet

Avelox_I.V. FDA

Avelox I.V. msds (material safety sheet)

Avelox_I.V. MSDS

Avelox I.V. Synthesis Reference

No information avaliable

Avelox I.V. Molecular Weight

401.431 g/mol

Avelox I.V. Melting Point

238-242 oC

Avelox I.V. H2O Solubility

No information avaliable

Avelox I.V. State


Avelox I.V. LogP


Avelox I.V. Dosage Forms

Solution (250 mL bags containing 400 mg of drug); Tablets (400 mg)

Avelox I.V. Indication

For the treatment of sinus and lung infections such as sinusitis, pneumonia, and secondary infections in chronic bronchitis. Also for the treatment of bacterial conjunctivitis (pinkeye).

Avelox I.V. Pharmacology

Moxifloxacin is a quinolone/fluoroquinolone antibiotic. Moxifloxacin can be used to treat infections caused by the following bacteria: Aerobic Gram-positive microorganisms: Corynebacterium species, Micrococcus luteus, Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus haemolyticus, Staphylococcus hominis, Staphylococcus warneri, Streptococcus pneumoniae, and Streptococcus viridans group. Aerobic Gram-negative microorganisms: Acinetobacter lwoffii, Haemophilus influenzae, and Haemophilus parainfluenzae. Other microorganisms: Chlamydia trachomatis.
Moxifloxacin is bactericidal and its mode of action depends on blocking of bacterial DNA replication by binding itself to an enzyme called DNA gyrase, which allows the untwisting required to replicate one DNA double helix into two. Notably the drug has 100 times higher affinity for bacterial DNA gyrase than for mammalian. Moxifloxacin is a broad-spectrum antibiotic that is active against both Gram-positive and Gram-negative bacteria.

Avelox I.V. Absorption

Well absorbed from the gastrointestinal tract. Absolute oral bioavailability is approximately 90%. Food has little effect on absorption.

Avelox I.V. side effects and Toxicity

Symptoms of overdose include CNS and gastrointestinal effects such as decreased activity, somnolence, tremor, convulsions, vomiting, and diarrhea. The minimal lethal intravenous dose in mice and rats is 100 mg/kg.

Avelox I.V. Patient Information

Avoid contaminating the applicator tip with material from the eye, fingers or other source. Systemically administered quinolones including moxifloxacin have been associated with hypersensitivity reactions, even following a single dose. Discontinue use immediately and contact your physician at the first sign of a rash or allergic reaction.

Avelox I.V. Organisms Affected

Enteric bacteria and other eubacteria